Argent Biopharma (AU:RGT) has released an update.
Argent BioPharma has secured A$200,000 through the issuance of 666,667 shares at A$0.30 each, a strategic move aimed at advancing their drug development projects, including CannEpil® and CimetrA®, in the US and EU markets. This share placement comes at a discount, potentially offering investors an attractive entry point into the company’s growth journey. With this funding, Argent BioPharma continues to strengthen its position within the biopharmaceutical sector.
For further insights into AU:RGT stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
